Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
IMUNON (Nasdaq: IMNN) reported that its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer is enrolling patients faster than planned. The company cites rapid site activation and a current study-level enrollment rate of about 0.5 patients per site per month, versus the trial plan assumption of 0.3 and historical ovarian cancer rates near 0.2.
More than 70% of sites are meeting or exceeding the 0.3 patients-per-month assumption. IMUNON now projects enrollment completion in the second quarter of 2029 and anticipates two pre-planned interim analyses, which could support an earlier BLA filing if pre-specified thresholds are met. Across OVATION 3 and an ongoing Phase 2 MRD study, IMNN-001 has shown a safety and tolerability profile with no observed cytokine release syndrome, systemic toxicities or serious immune-related adverse events, and recent Independent Data Monitoring Committee reviews have raised no safety issues.
IMUNON (Nasdaq: IMNN) will present new translational and clinical data on its DNA-based IL-12 immunotherapy IMNN-001 for advanced ovarian cancer at the inaugural AACR Drug Discovery and Development (AACR D3) conference, held July 21-24, 2026, in Boston.
The poster highlights IMUNON’s TheraPlas platform and randomized Phase 2 OVATION-2 data, where IMNN-001 plus chemotherapy showed numerical median overall survival of 40.5 vs. 27.6 months versus chemotherapy alone, along with local IL-12 delivery, favorable immune cell ratios, and a safety profile without cytokine release syndrome.
IMUNON (Nasdaq: IMNN) reported preliminary Phase 2 minimal residual disease (MRD) data for its IL‑12 DNA immunotherapy IMNN-001 in newly diagnosed advanced ovarian cancer, given with neoadjuvant/adjuvant chemotherapy plus bevacizumab. At second-look laparoscopy, 9 patients per arm had been evaluated.
According to IMUNON, IMNN-001 showed a lower MRD-positive rate vs. control (44% vs. 67%), higher circulating tumor DNA clearance (87.5% vs. 62.5%), and a numerically higher rate of no evidence of disease (100% vs. 56%) following frontline therapy. No cytokine release syndrome, systemic toxicities, or serious immune-related adverse events have been observed to date.
The MRD findings complement prior Phase 2 OVATION 2 data, where IMNN-001 plus chemotherapy was associated with median overall survival of 45.1 vs. 30.4 months, and 65.6 vs. 41.4 months in patients also receiving PARP maintenance. IMNN-001 is now in the pivotal Phase 3 OVATION 3 trial in frontline ovarian cancer.
IMUNON (Nasdaq: IMNN) reported that an independent Data Monitoring Committee recommended the Phase 3 OVATION 3 trial of IMNN-001 in advanced ovarian cancer continue without modification. The overall-survival-focused study has enrolled 27 of a planned ~80 patients and is targeting full enrollment by Q1 2027.
IMUNON (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will present at the Life Sciences Investor Forum on June 25, 2026, at 12:00 p.m. ET.
The live, interactive virtual event will include Q&A and a replay webcast.
IMUNON (Nasdaq: IMNN) entered definitive agreements for up to $10 million in cash financing, including $2.5 million of non-redeemable, non-convertible preferred stock and two secured promissory notes of $2.72 million and $5.0 million.
The notes accrue 8% and 5% annual interest, mature in 18 months, and interest will be partially offset by bank deposits. Net proceeds will support continued enrollment of the pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer.
Updated Phase 2 OVATION 2 data show median overall survival improving from 11.1 to 14.7 months, and a 24.2‑month median increase versus standard chemotherapy when IMNN-001 and PARP inhibitors are added.
IMUNON (NASDAQ: IMNN) reported first quarter 2026 net loss of $4.3 million, or $0.84 per share, with operating expenses of $4.3 million and cash and equivalents of $4.8 million.
Phase 2 OVATION 2 data for IMNN-001 showed median overall survival gains up to 24.2 months and a favorable safety profile, supporting the ongoing Phase 3 OVATION 3 trial, which has FDA-aligned protocol and a defined path to BLA filing.
IMUNON (NASDAQ: IMNN) will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to report first quarter results for the period ended March 31, 2026 and provide an update on Phase 3 clinical development of lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.
Live dial-in and webcast access will be provided; an audio replay will be available for 90 days.
IMUNON (Nasdaq: IMNN) reported 2025 results and clinical progress on IMNN-001 for newly diagnosed advanced ovarian cancer. Final Phase 2 OVATION 2 data show continued median overall survival improvement: 14.7 months benefit (45.1 vs. 30.4 months) versus standard of care, and 24.2 months with PARP inhibitor maintenance (65.6 vs. 41.4 months).
Corporate actions include a December 2025 at-the-market registered direct offering (~$7.0M) and a strategic reorganization; 2025 net loss was $14.5M and year-end cash was $8.8M.
IMUNON (Nasdaq: IMNN) reported final Phase 2 OVATION 2 results showing an improved median overall survival (OS) benefit for IMNN-001 plus standard chemotherapy: a 14.7-month OS increase (45.1 vs. 30.4 months) versus SoC alone. Women receiving IMNN-001 plus PARP inhibitor maintenance showed a 24.2-month OS increase (65.6 vs. 41.4 months).
OVATION 2 randomized 112 patients. IMUNON says Phase 3 OVATION 3 enrollment is ahead of plan, currently open at seven sites with up to 43 sites considered and ~80 patients (~20% of 500 target) expected within a year; two interim OS analyses are planned.